Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2019; 11(04): 340-345
DOI: 10.4103/JLP.JLP_39_19
Original Article

Recent pattern of antibiotic resistance in Staphylococcus aureus clinical isolates in Eastern India and the emergence of reduced susceptibility to vancomycin

Srujana Mohanty
Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
,
Bijayini Behera
Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
,
Subhrajyoti Sahu
Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
,
Ashok Kumar Praharaj
Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

PURPOSE: We aimed to determine the recent pattern of antibiotic resistance and assess the vancomycin susceptibility profile of clinical Staphylococcus aureus in view of emerging reports of vancomycin creep, reduced vancomycin susceptibility (RVS), including heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus, and vancomycin resistance in S. aureus isolates.

MATERIALS AND METHODS: Consecutive, nonduplicate isolates of S. aureus between July 2015 and June 2016 were subjected to antimicrobial susceptibility testing using standard disk diffusion test or Etest as per the Clinical and Laboratory Standards Institute 2015. Detection of hVISA was done by glycopeptide resistance detection Etest according to the manufacturer's instructions in strains with vancomycin minimum inhibitory concentration of 1–2 μg/ml.

RESULTS: A total of 284 S. aureus were obtained from pus (175, 61.6%), respiratory tract (31, 10.9%), urine (27, 9.5%), blood (25, 8.8%), body fluids (18, 6.3%), and catheter tips (8, 2.8%). 127 (44.7%) isolates were methicillin resistant, and 158 (55.6%) were multidrug resistant. High resistance was observed to penicillin (81.7%), erythromycin (62.3%), and ciprofloxacin (52.1%), whereas the resistance was low to gentamicin (5.3%), rifampicin (8.1%), and doxycycline (9.5%). Two hundred and fifty-one (88.3%) isolates were fully susceptible to vancomycin, whereas 33 (11.6%) demonstrated RVS. All were uniformly susceptible to linezolid, tigecycline, and daptomycin.

CONCLUSIONS: A moderately high percentage of S. aureus isolates demonstrated RVS, which may limit its usefulness in methicillin-resistant isolates and may be associated with increased complications in methicillin-susceptible infections. In view of increasing glycopeptide resistance, the susceptibility status of vancomycin along with other antibiotics among clinical S. aureus isolates should be investigated periodically.

Keywords

Heterogenous vancomycin-intermediate Staphylococcus aureus - methicillin-resistant Staphylococcus aureus - Staphylococcus aureus - vancomycin - vancomycin-intermediate Staphylococcus aureus


Publication History

Received: 03 March 2019

Accepted: 09 September 2019

Article published online:
07 April 2020

© 2019.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46 Suppl 5:S344-9.
  • 2 Valle DL Jr., Paclibare PA, Cabrera EC, Rivera WL. Molecular and phenotypic characterization of methicillin-resistant Staphylococcus aureus isolates from a tertiary hospital in the Philippines. Trop Med Health 2016;44:3.
  • 3 Koh YR, Kim KH, Chang CL, Yi J. Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients. Ann Lab Med 2016;36:235-43.
  • 4 Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139.
  • 5 Hu J, Ma XX, Tian Y, Pang L, Cui LZ, Shang H. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China. PLoS One 2013;8:e73300.
  • 6 Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Siu LK, et al. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan medical center. J Microbiol Immunol Infect 2012;45:435-41.
  • 7 Aguado JM, San-Juan R, Lalueza A, Sanz F, Rodríguez-Otero J, Gómez-Gonzalez C, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 2011;17:1099-102.
  • 8 San-Juan R, Viedma E, Chaves F, Lalueza A, Fortún J, Loza E, et al. High MICs for vancomycin and daptomycin and complicated catheter-related bloodstream infections with methicillin-sensitive Staphylococcus aureus. Emerg Infect Dis 2016;22:1057-66.
  • 9 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 16th Informational Supplement. Clinical and Laboratory Standards Institute Document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
  • 10 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 19th Informational Supplement. Clinical and Laboratory Standards Institute Document M100-S19. 19th ed.. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
  • 11 Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009;63:489-92.
  • 12 Di Gregorio S, Perazzi B, Ordoñez AM, De Gregorio S, Foccoli M, Lasala MB, et al. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist 2015;21:25-34.
  • 13 Holubar M, Meng L, Deresinski S. Bacteremia due to methicillin-resistant Staphylococcus aureus: New therapeutic approaches. Infect Dis Clin North Am 2016;30:491-507.
  • 14 Culos KA, Cannon JP, Grim SA. Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Am J Ther 2013;20:200-12.
  • 15 Menezes GA, Harish BN, Sujatha S, Vinothini K, Parija SC. Emergence of vancomycin-intermediate Staphylococcus species in Southern India. J Med Microbiol 2008;57:911-2.
  • 16 Chaudhari CN, Tandel K, Grover N, Sen S, Bhatt P, Sahni AK, et al. Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus. Med J Armed Forces India 2015;71:15-8.
  • 17 Bakthavatchalam YD, Veeraraghavan B, Peter JV, Rajinikanth J, Inbanathan FY, Devanga Ragupathi NK, et al. Novel observations in 11 heteroresistant vancomycin-intermediate methicillin-resistant Staphylococcus aureus strains from South India. Genome Announc 2016;4. pii: e01425-16.
  • 18 Jain S, Gaind R, Chugh TD.In vitro activity of vancomycin and daptomycin against clinical isolates of Staphylococcus aureus and enterococci from India. Int J Antimicrob Agents 2013;42:94-5.
  • 19 Singh A, Prasad KN, Misra R, Rahman M, Singh SK, Rai RP, et al. Increasing trend of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of Northern India. Microb Drug Resist 2015;21:545-50.
  • 20 Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. London: Churchill Livingstone; 1996. p. 131-45.
  • 21 Clinical and Laboratory Standards Institute. Performance Standards for antimicrobial Susceptibility Testing: 25th Informational Supplement. Clinical and Laboratory Standards Institute Document M100-S25. 25th ed.. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
  • 22 Holmes NE, Johnson PD, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012;50:2548-52.
  • 23 Pfizer Inc. (Wyeth Pharmaceuticals): Tygacil® Product Insert. Pfizer; 2013. Available from: http://www.pfizerpro.com/hcp/tygacil. [Last accessed on 2016 Jul 15].
  • 24 Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
  • 25 Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. Methicillin resistant Staphylococcus aureus (MRSA) in India: Prevalence and susceptibility pattern. Indian J Med Res 2013;137:363-9.
  • 26 Anupurba S, Sen MR, Nath G, Sharma BM, Gulati AK, Mohapatra TM. Prevalence of methicillin resistant Staphylococcus aureus in a tertiary referral hospital in Eastern Uttar Pradesh. Indian J Med Microbiol 2003;21:49-51.
  • 27 Tiwari HK, Sapkota D, Sen MR. High prevalence of multidrug-resistant MRSA in a tertiary care hospital of Northern India. Infect Drug Resist 2008;1:57-61.
  • 28 Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res 2011;134:704-8.
  • 29 Taj Y, Abdullah FE, Kazmi SU. Current pattern of antibiotic resistance in Staphylococcus aureus clinical isolates and the emergence of vancomycin resistance. J Coll Physicians Surg Pak 2010;20:728-32.
  • 30 Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009;49:1169-74.